This review highlights computer-aided drug discovery strategies for viral proteins, suggesting advances in targeting novel chemotypes.
The absence of 3D structures for most viral proteins has limited the identification of novel chemotypes through CADD approaches. Furthermore, the lack of biological validation after in silico studies may slow down progress in this field, as researchers might focus on compounds that seem promising only at the computational level. Emerging systems such as human intestinal enteroids, together with AI/ML augmented CADD, can accelerate optimization and triage of non-nucleoside and covalent protease inhibitors.
No takes yet. Share an insight, caveat, or question.
Palazzo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: